Royal London Asset Management Ltd. Has $13.30 Million Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Royal London Asset Management Ltd. lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 4.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 170,949 shares of the medical device company's stock after purchasing an additional 7,711 shares during the period. Royal London Asset Management Ltd.'s holdings in DexCom were worth $13,295,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Geode Capital Management LLC lifted its holdings in DexCom by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company's stock worth $664,056,000 after buying an additional 214,136 shares in the last quarter. Jennison Associates LLC raised its position in shares of DexCom by 10.3% during the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock worth $594,455,000 after acquiring an additional 710,858 shares during the last quarter. Groupama Asset Managment lifted its stake in shares of DexCom by 1.1% during the third quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company's stock valued at $1,912,000 after acquiring an additional 31,358 shares during the period. Westfield Capital Management Co. LP boosted its holdings in DexCom by 44.6% in the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company's stock valued at $190,532,000 after acquiring an additional 876,739 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in DexCom by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company's stock worth $219,716,000 after purchasing an additional 91,051 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analyst Weigh In

A number of research analysts have issued reports on DXCM shares. Morgan Stanley upped their target price on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Cfra Research raised shares of DexCom to a "hold" rating in a research note on Friday, March 21st. Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Citigroup increased their price target on DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. Finally, Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and lifted their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $99.82.

DexCom Stock Down 1.9 %

Shares of NASDAQ:DXCM traded down $1.42 during midday trading on Wednesday, reaching $72.13. 3,271,213 shares of the company were exchanged, compared to its average volume of 3,865,415. The firm has a market cap of $28.19 billion, a PE ratio of 50.44, a P/E/G ratio of 2.30 and a beta of 1.28. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $141.99. The stock has a fifty day simple moving average of $83.13 and a two-hundred day simple moving average of $77.11.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, sell-side analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Transactions at DexCom

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the sale, the executive vice president now directly owns 83,526 shares in the company, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin R. Sayer sold 32,498 shares of the firm's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the transaction, the chief executive officer now owns 372,029 shares of the company's stock, valued at $26,183,401.02. The trade was a 8.03 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 105,009 shares of company stock valued at $8,044,178 over the last 90 days. 0.30% of the stock is owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.